Perelman M - Search Results

1

Evidence for Alpha₇ Nicotinic Receptor Activation During the Cough Suppressing Effects Induced by Nicotine and Identification of ATA-101 as a Potential Novel Therapy for the Treatment of Chronic Cough.

Canning BJ, Liu Q, Tao M, DeVita R, Perelman M, Hay DW, Dicpinigaitis PV, Liang J. Canning BJ, et al. Among authors: perelman m. J Pharmacol Exp Ther. 2022 Feb;380(2):94-103. doi: 10.1124/jpet.121.000641. Epub 2021 Nov 15. J Pharmacol Exp Ther. 2022. PMID: 34782407 Free PMC article.

2

Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl.

Perelman M, Fisher AN, Smith A, Knight A. Perelman M, et al. Int J Clin Pharmacol Ther. 2013 May;51(5):349-56. doi: 10.5414/CP201825. Int J Clin Pharmacol Ther. 2013. PMID: 23458227 Clinical Trial.

3

A pharmacokinetic assessment of an alternate titration strategy for fentanyl pectin nasal spray.

Perelman M, Knight A. Perelman M, et al. Int J Clin Pharmacol Ther. 2013 Dec;51(12):942-7. doi: 10.5414/CP201913. Int J Clin Pharmacol Ther. 2013. PMID: 24120713 Clinical Trial.

4

Development of in vitro models to demonstrate the ability of PecSys®, an in situ nasal gelling technology, to reduce nasal run-off and drip.

Castile J, Cheng YH, Simmons B, Perelman M, Smith A, Watts P. Castile J, et al. Among authors: perelman m. Drug Dev Ind Pharm. 2013 May;39(5):816-24. doi: 10.3109/03639045.2012.707210. Epub 2012 Jul 17. Drug Dev Ind Pharm. 2013. PMID: 22803832 Free PMC article.

5

Nasal delivery of fentanyl.

Watts P, Smith A, Perelman M. Watts P, et al. Among authors: perelman m. Drug Deliv Transl Res. 2013 Feb;3(1):75-83. doi: 10.1007/s13346-012-0078-y. Drug Deliv Transl Res. 2013. PMID: 25787867

6

Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines.

Smith A, Perelman M, Hinchcliffe M. Smith A, et al. Among authors: perelman m. Hum Vaccin Immunother. 2014;10(3):797-807. doi: 10.4161/hv.27449. Epub 2013 Dec 17. Hum Vaccin Immunother. 2014. PMID: 24346613 Free PMC article. Review.

7

Relationship between onset of pain relief and patient satisfaction with fentanyl pectin nasal spray for breakthrough pain in cancer.

Torres LM, Revnic J, Knight AD, Perelman M. Torres LM, et al. Among authors: perelman m. J Palliat Med. 2014 Oct;17(10):1150-7. doi: 10.1089/jpm.2014.0089. Epub 2014 Sep 11. J Palliat Med. 2014. PMID: 25211772

8

An analysis of the variability of breakthrough pain intensity in patients with cancer.

Burton AW, Filbet M, Knight AD, Tayi R, Perelman M. Burton AW, et al. Among authors: perelman m. J Community Support Oncol. 2014 Mar;12(3):99-103. doi: 10.12788/jcso.0026. J Community Support Oncol. 2014. PMID: 24971415

9

A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain.

Taylor D, Radbruch L, Revnic J, Torres LM, Ellershaw JE, Perelman M. Taylor D, et al. Among authors: perelman m. J Pain Symptom Manage. 2014 Jun;47(6):1001-7. doi: 10.1016/j.jpainsymman.2013.07.012. Epub 2013 Oct 12. J Pain Symptom Manage. 2014. PMID: 24128821 Free article. Clinical Trial.

10

Efficacy, safety, and tolerability of fentanyl pectin nasal spray in patients with breakthrough cancer pain.

Ueberall MA, Lorenzl S, Lux EA, Voltz R, Perelman M. Ueberall MA, et al. Among authors: perelman m. J Pain Res. 2016 Aug 17;9:571-85. doi: 10.2147/JPR.S106177. eCollection 2016. J Pain Res. 2016. PMID: 27574463 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

378 results

Search Page

Filters